Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Another Midatech Deal Coming for Bioasis??
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Feb 15, 2023 6:28pm
140 Views
Post# 35288656

RE:RE:RE:RE:Another Midatech Deal Coming for Bioasis??

RE:RE:RE:RE:Another Midatech Deal Coming for Bioasis??As I posted, ROSIE2023, I agree with you that the deal has been terminated but if both sides suddenly said, "Well, wait a minute...!"

There is nothing stopping Midatech, Bioasis, Ladenburg Thalmann and the placees from going at it all over again, figuring that Midatech and Bioasis shareholders, who have had a recent near-death experience, might well give up and go for the deal.

xB3, if it works as hoped, will be a big win for whoever has it. I believe they may go for it again.

Rathjen in the deal termination PR expressed her disappointment that Midatech shareholders voted the deal down. And then Bioasis shareholders voted for the deal.

She's shameless. She'll do it again and this time it will go through.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities